NIH Multiyear Lump-Sum Funding for R01s

Since fiscal year 2025, the National Institutes of Health has been shifting a growing share of its Research Project Grant (RPG) budget from incremental funding (one budget period’s worth of money issued per year, with the remaining years contingent on continued appropriations and satisfactory progress) to multiyear lump-sum, or “forward,” funding — awarding a grant’s entire project-period budget in a single obligation in the year it is first funded. NIH has continued and expanded this practice into FY2026, and Congress, in the FY2026 appropriations act, capped how far NIH can take it. This guide explains what forward funding actually changes operationally, how the FY2026 cap works, and what it means for institutions planning around R01 and other competing awards.

What “multiyear lump-sum” funding means, operationally

Under standard incremental funding, a multi-year NIH award (a typical R01 runs four or five years) is obligated one budget period at a time. The Notice of Award for year one covers year one’s direct and indirect costs; years two through five are “committed” on paper in the Notice of Award’s future-year estimates but each year’s actual funds are obligated only when that year’s appropriation is available and the grantee’s progress report is accepted. This is the funding pattern research administrators have built budget-projection and carryover practices around for decades.

Under multiyear lump-sum (forward) funding, NIH instead obligates the entire project period’s budget — all years at once — out of a single fiscal year’s appropriation, at the time of the initial award. A five-year R01 that would previously have drawn roughly one-fifth of its total cost from each of five annual appropriations instead draws its full total cost from the single appropriation available in its first year.

The mechanism itself is not new — NIH has long forward-funded certain award types where obligating the full amount up front makes administrative sense (some fellowship and training awards, AREA/R15 grants, and select infrastructure programs). What changed starting in FY2025 is the extension of forward funding to standard competing Research Project Grants, including R01s, at scale, as a deliberate budget-execution policy rather than a mechanism-specific exception.

Why NIH adopted this approach

NIH’s stated rationale, reflected in agency budget documents, is that incremental funding permanently “encumbers” a large share of every year’s appropriation for continuing obligations to grants awarded in prior years — money that is already spoken for before a single new competing application can be funded that year. Forward-funding a project’s full cost at the point of award removes that project from future years’ continuation-funding queue entirely, which NIH describes as increasing budget flexibility in later fiscal years. The trade-off is immediate: fully funding a grant’s later years today consumes more of the current year’s appropriation up front, leaving less available in the current year for new competing awards.

Which awards it applies to

Forward funding has been applied unevenly across activity codes. Reporting drawing on NIH’s own award data indicates that R21 exploratory/developmental awards have made up the largest share of multiyear-funded competing RPGs issued so far in FY2026, with R01s representing a smaller but still substantial share. (REPORTED tier — figures here are sourced from secondary aggregation of NIH award data by research-policy outlets rather than a directly fetched NIH primary table; grants.nih.gov and nih.gov budget pages returned access errors to direct fetch during this review, a recurring pattern for this domain — treat exact percentages as indicative rather than load-bearing until checked against NIH’s own current RPG funding-mechanism table.) Institutions should not assume every competing R01 notice of award in FY2026 will be forward-funded — check each specific Notice of Award’s obligated amount against its approved budget for all years, rather than assuming based on activity code alone.

The FY2026 appropriations cap

The FY2026 President’s Budget request proposed expanding forward funding further — reportedly toward reserving roughly half of NIH’s competing-RPG allocation for multiyear-funded awards. Congress did not adopt that expansion. The Consolidated Appropriations Act, 2026 (Public Law 119-75), enacted February 2026, includes a provision in Division B (the Labor-HHS-Education title) — Section 240, per Congressional Research Service tracking of the act — that caps the amount NIH may obligate for multiyear awards at the same level obligated for multiyear awards in FY2025. In effect, Congress froze forward funding at its FY2025 level rather than allowing it to expand as the FY2026 budget request proposed.

NIH’s own NOT-OD-26-060, “Notice of Legislative Mandates in Effect for FY 2026,” is the NIH Guide notice that compiles the appropriations-act riders and mandates NIH staff and awardees are expected to operate under for the fiscal year, and is the primary source to check for the current, authoritative statement of this and other FY2026 appropriations conditions (including the separate indirect-cost-rate rider discussed below). Because NIH policy notices are periodically updated and appropriations riders are typically renewed or revised year to year, confirm the current-year notice number and language directly before citing a specific dollar cap or percentage in a proposal or institutional guidance document.

This provision has been reported consistently across Congressional Research Service tracking and research-policy outlets (AAMC, Inside Higher Ed, Science) as of mid-2026; direct WebFetch access to grants.nih.gov and nih.gov primary pages was intermittently blocked during this review (a recurring access pattern for this domain noted elsewhere on this site), so treat the exact statutory language as REPORTED-tier pending direct confirmation against NOT-OD-26-060 or the enacted appropriations text itself.

Do not confuse this with the NIH indirect-cost-rate cap fight

Because both disputes involve NIH, Congress, and FY2026 appropriations, it is easy to conflate the multiyear-funding cap with NIH’s separate, better-known effort to cap negotiated indirect-cost (F&A) rates at a flat 15%. They are unrelated policy questions decided through different mechanisms:

The indirect-cost cap is a proposal to change how much of a grant’s budget covers facilities-and-administrative costs, blocked separately by litigation and by a recurring appropriations rider barring HHS from implementing a modified indirect-cost methodology. See CASRAI’s guide to NIH’s 15% indirect cost cap and the fuller NIH indirect cost policy guide for that fight specifically.
The multiyear-funding cap covered on this page is about when a grant’s already-approved budget is obligated — up front in one year, or spread annually — and is capped by a specific appropriations-act provision (Division B, Section 240 of P.L. 119-75) limiting the practice to FY2025 levels, independent of the indirect-cost dispute.

An institution can be affected by one, both, or neither in a given award cycle — they should be tracked and budgeted for separately.

Effect on new and noncompeting awards

Because forward funding shifts a larger share of a fixed annual appropriation into up-front obligations for a smaller number of grants, its most direct consequence is fewer dollars left for new competing awards in the same fiscal year, even without any change to NIH’s total budget. Institute-level FY2026 budget documents reflect this: several Institutes and Centers report funding noncompeting (continuing) RPGs below full committed levels — around 10% below full commitment in at least one Institute’s published FY2026 budget justification — and reduced numbers of total RPGs funded relative to FY2025. Reporting citing NIH’s own projections has put the FY2026 reduction in competing grants attributable to the forward-funding policy at several hundred to roughly a thousand fewer new awards agency-wide; treat the specific figure as REPORTED-tier (secondary-sourced, not independently confirmed against a single NIH primary table) and verify against current-year NIH RPG success-rate data before citing a precise number.

The effect is visible in success-rate trends independent of any single figure: early-stage-investigator success rates have declined across FY2023-FY2025 and are tracking lower still in FY2026 per multiple secondary reports, consistent with a smaller pool of new awards competing for a fixed appropriation. See CASRAI’s guide on NIH R01 success rates and paylines by institute for how to find and read current, institute-specific numbers rather than relying on agency-wide averages.

What research administrators should do

Check each Notice of Award, not the activity code. Whether a specific R01 was forward-funded is determined by the obligated amount on its actual Notice of Award, not by assumption. A forward-funded award has little or no future “committed but unobligated” balance shown for out-years; an incrementally funded award still shows future years as estimated, unobligated commitments.
Recognize the budget-planning implications of full up-front obligation. A forward-funded grant does not need an annual continuation (Type 5 noncompeting) progress report and funding action to release the next year’s money in the same way an incrementally funded award does, which changes what a sponsored-programs office needs to track for that award’s out-years — though annual progress reporting (RPPR) obligations under the terms of award are unaffected by how the funds were obligated.
Factor a tighter competing-award environment into strategy conversations with PIs. With a fixed or shrinking pool of dollars available for new competing awards in a given fiscal year, institutions should expect paylines and success rates to remain under pressure independent of any change in application quality — see the R01 success rates and paylines guide and, for an alternative mechanism worth considering in that environment, the R01 vs. R21 comparison.
Track the appropriations cycle, not just NIH policy notices. Because the FY2026 cap on forward funding is a statutory appropriations provision rather than a standing NIH policy, it is subject to change (upward or downward) in each year’s appropriations act. Confirm the current fiscal year’s cap language in that year’s “Notice of Legislative Mandates” NIH Guide notice before relying on the FY2026 figures cited here for a future fiscal year.
Distinguish this from other FY2026 NIH funding-process changes happening in parallel, including changes to how NIH posts funding opportunities — see CASRAI’s guide to the FY2026 NOFO overhaul — and the general shifting terrain covered in the NIH government shutdown impact guide, all of which affect the same FY2026 funding environment through different mechanisms.

Frequently asked questions

Is multiyear lump-sum funding the same as a noncompeting continuation award?

No. A noncompeting (Type 5) continuation is a separate annual funding action within an incrementally funded award’s project period. Forward funding eliminates the need for that separate annual action for the years it covers, because the entire project period was already obligated at the initial award. See CASRAI’s comparison of competing vs. noncompeting renewals for how the standard incremental process works.

Does forward funding change how much total money my award receives?

Not directly — a forward-funded award’s total approved budget across its project period is unchanged; only the timing of obligation changes. The indirect effect is on the broader funding environment: forward-funding a larger share of continuing grants leaves fewer dollars available for new competing awards in a given year, which can affect success rates and paylines for future applications, including competing renewals.

Can NIH forward-fund my R01 without telling me?

The Notice of Award for a forward-funded grant will show the full multiyear obligated amount rather than a single budget period’s amount; this is visible on the Notice of Award itself and in eRA Commons, not something announced separately. Sponsored-programs offices should review each Notice of Award’s obligated amount against the approved budget to confirm which funding pattern applies.

Is the FY2026 cap on forward funding likely to change in FY2027?

It is an annual appropriations-act provision, not a permanent statute, so it can be renewed, loosened, or tightened in each year’s Labor-HHS appropriations act. Given that the administration’s FY2026 budget request already sought a larger expansion than Congress granted, the FY2027 appropriations cycle is worth watching for a renewed push in either direction, similar to the pattern seen in NIH’s separate indirect-cost-rate rider, which Congress has renewed annually since FY2018.

NIH’s Multiyear Lump-Sum Funding for R01s and the FY2026 Appropriations Cap